Designing Rare Disease Care Pathways in the Republic of Ireland –
A Co-operative Model

A J Ward
Mater Misericordiae University Hospital

Daniel Murphy
Mater Misericordiae University Hospital

Rita Marron
Mater Misericordiae University Hospital

V McGrath
Rare Diseases Ireland

M Bolz-Johnson
Eurordis

Walter Cullen
University College Dublin

Avril Daly
Eurordis

Orla Hardiman
Trinity College

A Lawlor
22Q11 Ireland

Sally Ann Lynch
University College Dublin - National University of Ireland: University College Dublin

Mac MacLachlan
Maynooth University: National University of Ireland Maynooth

Jackie McBrien
Childrens Hospital Ireland

James O'Byrne
Mater Misericordiae University Hospital

Jacqueline Turner
Mater Misericordiae University Hospital

Susan O'Connell
CHI at OLCHC, Dublin

Eileen P Treacy (etreacy@mater.ie)
Mater Misericordiae University Hospital

https://orcid.org/0000-0002-6226-1615

Research Article

Keywords: Rare Diseases, Care Pathways, Ireland

Posted Date: January 17th, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1225286/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Rare diseases (RDs) are often complex, serious, chronic and multi-systemic conditions, associated with physical, sensory and intellectual disability. Patients require follow-up management from multiple medical specialists and health and social care professionals (HSCPs) involving a high level of integrated care, service coordination and specified care pathways.

**Methods and Objectives:** This pilot study aimed to explore the best approach for developing national RD care pathways in the Irish healthcare system in the context of a lack of agreed methodology. Irish clinical specialists and patient/lived experience experts were asked to map existing practice against evidence-based Clinical Practice Guidelines (CPGs) and best practice recommendations from the European Reference Networks (ERNs) to develop optimal care pathways. The study focused on the more prevalent, multisystemic rare conditions that require multidisciplinary care, services, supports and therapeutic interventions.

**Results:** 29 rare conditions were selected across 18 ERNs, for care pathway development. Multidisciplinary input from multiple specialisms was relevant for all pathways. A high level of engagement was experienced from clinical leads and patient organisations. CPGs were identified for 26 of the conditions. Nurse specialist, Psychology, Medical Social Work and Database Manager roles were deemed essential for all care pathways. Access to the therapeutic Health Service Professionals: Physiotherapy, Occupational Therapy, and Speech and Language Therapy were seen as key requirements for holistic care. Genetic counselling was highlighted as a core discipline in 27 pathways demonstrating the importance of access to Clinical Genetics services for many people with RDs.

**Conclusions:** This study proposes a methodology for Irish RD care pathway development, in collaboration with patient/service user advocates. Common RD patient needs and health care professional interventions across all pathways were identified. Key RD stakeholders have endorsed this national care pathway initiative. Future research focused on the implementation of such care pathways is a priority.

**Background**

In Europe, a rare disease (RD) is defined as a condition with less than five affected persons per 10,000 (1). It is estimated that 300,000 people in Ireland are living with one of over 6,000 known RDs (2). These conditions tend to be complex, serious, debilitating, chronic and multi-systemic, often associated with physical, sensory and intellectual disability. In many cases patients require follow-up care with management from multiple medical specialists and health and social care professionals, which necessitates a high level of integrated care and service coordination between hospital, community, social and primary care services (3).

People with RDs experience significant challenges in securing diagnoses and accessing appropriate coordinated services, care and treatment (4, 5). Patients/service users and carers/supporters report that lack of care coordination is a central barrier to accessing timely interventions and has a major impact on health and well-being (6, 7).

Ineffective use of resources due to fragmented services can prolong the ‘diagnostic odyssey’ for many people with RDs (8). Health care professionals (HCPs) from primary through to tertiary care report a lack of access to RD educational opportunities and struggle to meet the needs of people with RDs (9, 10, 11). Care pathways and defined standards for rare conditions are lacking (12). Consequently, people with RDs access a disproportionate level of health care resources (13, 14). The COVID-19 pandemic has further highlighted existing healthcare challenges for people with RDs and the need for more resilient healthcare systems which incorporate telemedicine (15, 16).

Development and implementation of RD care pathways strongly aligns with Irish national health service priorities as outlined in the Model of Care for Rare Diseases 2019 (17), with a focus on delivering more integrated care locally through the national Sláintecare Health Reform Programme 2021-2023 (18).

At a European Union level, member states are committed to facilitating equitable access to timely assessment and diagnosis and high quality, cost-effective care for all people with RDs, and to incorporate rare diseases into social services and policies (19, 20). In 2017, 24 European Reference Networks (ERNs), virtual networks of healthcare providers across the European Union, were launched to improve RD patient outcomes by enhancing access to specialised education of healthcare professionals (HCPs), developing and endorsing best practice guidelines, providing virtual expert consultations for complex cases and promoting clinical research activity (21). The ERN Board of Member States (2019) considers the development of national RD patient care pathways as central in the integration of ERNs into member states (22).

Care Pathways are complex interventions that organize care for a well-defined group of patients for a well-defined period (23). They can be at a system, service or individual care level, have varying levels of granularity and can be multi-professional typically incorporating
multiple guidelines (24).

**Methodology for developing a care pathway**

Whilst there is internationally agreed best practice methodology for the development of CPGs, there is no commonly recognised methodology for care pathways. Achieving international consensus on care pathway design methodology is complicated by the heterogeneity of national healthcare systems. However, it is agreed that co-design with patient partners is essential (25, 26). ‘RarERN Path’ has defined a model for care pathway development that is based on capturing existing practice through a narrative medicine approach and achieving patient, carer and HCP consensus on an optimized pathway (27). Patients accessing evidence-based care have increased health outcomes and their care is more cost effective (28, 29). Care pathways increase evidence-based care and improve care process coordination (23, 30). However, identifying robust CPGs for RDs can be challenging due to limited randomized control trial data (31).

This pilot study explored the optimal approach to developing Irish RD care pathways by focusing 29 multi-systemic conditions. A secondary objective was to establish the resources needed to implement each care pathway at the national level.

**Methods**

**Condition selection**

We initially selected 30 rare conditions, across 18 ERNs, due to their estimated higher prevalence in the Irish population, based on preliminary data derived from the Irish ERN applications and Orphanet data (32). Conditions were considered only if they were multi-systemic and chronic in nature requiring multidisciplinary care and services. Rare cancers and rare infectious diseases were not included, as these do not fall under the remit of the Irish National Rare Diseases Office (NRDO) but are covered, in Ireland, by separate national health service policy, commissioning and clinical governance structures.

**Care Pathway Model**

The initial care pathway model structure was designed based on input from several hospital consultant medical lead collaborators, with four over-arching key categories under which the medical and HSCP disciplines and interventions could be placed and detailed:

1. Diagnosis
2. Hospital-based specialist care
3. Hospital and community-based care
4. Primary and community-driven care

For certain conditions, it was necessary to include an additional category to reflect service and support intervention delivery models. For example, a ‘Children's Disability Network Team (CDNT)’ category was added to the 22q11 deletion syndrome and Angelman syndrome care pathways to capture recently completed reconfiguration within children's disability services in Ireland. The Amyotrophic Lateral Sclerosis (ALS) care pathway included a specific category called ‘Specialist MND Multidisciplinary Clinic’ to accurately reflect how services for ALS are currently delivered (Figure 3). To allow the interactive capacity of the model to be realised, a purpose-designed Microsoft ‘Teams’ LucidChart was developed. This allows the details for each section to be revealed and cleared as users move through the pathway by clicking on the drop-down menus to select specific information.

**Preliminary Care Pathway Development**

A review of existent CPGs, published within the last 10 years, was performed for each condition by searches of Pubmed, Cochrane, Orphanet and relevant ERN websites. Preliminary care pathways were designed based on the guidelines identified in this evidence-based review. Detailed information about diagnosis, laboratory testing, investigations, management and treatment was recorded under the relevant medical and HSCP disciplines to create a preliminary care pathway for each condition.

**Clinical Leads**

Expert Irish clinical leads were identified for each condition by liaising with National Reference Network Centres connected under the ERNs as registered on the Irish Orphanet site. For those conditions with possible paediatric onset associated with lifelong care, both paediatric and adult clinical leads were identified. Clinical Leads were asked to map the preliminary care pathways onto existent Irish healthcare services and structures to develop optimal care pathways. The Clinical leads engaged with multidisciplinary teams (MDTs) and professionals from other disciplines for detailing of specific sections, where appropriate.

**Patient Representatives**
A co-ordinating patient/service user representative was identified for each condition by the Irish national patient rare disease alliance - ‘Rare Diseases Ireland’ (RDI) in liaison with the national patient organisations listed on Orphanet. For several conditions, where no specific Irish patient organisation exists, clinical leads were asked to nominate an appropriate patient representative. RDI also liaised with relevant UK support groups to identify possible additional Irish patient representatives, as on occasion Irish patients join UK support groups where no group is available in Ireland. The patient/service user representative co-ordinators for each condition were sent the relevant care pathway document and asked to invite key patient advocates from their network to attend an online workshop jointly led by RDI and NRDO with co-created support materials. The main objectives of these workshops were: to create a supportive space for collaboration and sharing of experiential knowledge; to better understand the common needs and interventions which patients with rare diseases prioritise; and to enhance the relevance and utility of the care pathways.

A range of forums for contributions were utilised due to the diverse operational structures of the patient organisations involved: patient representative co-ordinators out-reach within their networks; establishment of short-term working groups; review by patient organisation boards; direct liaison of patient representatives with clinical leads. Patient representative feedback was reviewed by the relevant clinical lead(s) before integration to ensure safe clinical governance over the content. These care pathways were presented to patient representatives for final review.

**Primary care**

Engagement with primary care HCPs was sought to ensure that rare disease care pathways best represent the role of General Practitioners (GPs). This aimed to better understand and address the needs of GPs at key points of contact with people with RDs around diagnosis, care and management.

**Results**

**Conditions Selected**

Of the 30 rare conditions initially selected for care pathway development one was not progressed due to local low population prevalence. Table 1 illustrates the conditions studied.
Table 1
29 rare conditions selected for care pathway development across 18 ERNs

| ERN          | Orphanet Disease                  | ORPHAcode |
|--------------|-----------------------------------|-----------|
| Endo-ERN     | Turner syndrome                   | 99413     |
| Endo-ERN     | Primary Adrenal Insufficiency      | 101958    |
| ERKNet       | Glomerular disease                 | 183586    |
| ERN BOND     | Osteogenesis Imperfecta           | 666       |
| ERN BOND     | Hypophosphataemic Rickets          | 437       |
| ERN EpiCARE  | Tuberous Sclerosis                | 805       |
| EuroBloodNet | Sickle Cell Anaemia                | 232       |
| EuroBloodNet | Von Willebrand disease            | 903       |
| ERN EURO-NMD | Duchenne Muscular Dystrophy        | 98896     |
| ERN EURO-NMD | Amyotrophic Lateral Sclerosis      | 803       |
| ERN EYE      | Retinitis Pigmentosa               | 791       |
| ERN EYE      | Usher Syndrome                     | 886       |
| ERN GENTURIS | Neurofibromatosis type 1           | 636       |
| ERN GUARD-HEART | Long QT syndrome                | 768       |
| ERN ITHACA   | 22q11.2 deletion syndrome          | 567       |
| ERN ITHACA   | Angelman syndrome                  | 72        |
| ERN LUNG     | Sarcoidosis                        | 797       |
| ERN RARE-LIVER | Wilson Disease                   | 905       |
| ERN ReCONNET | Ehlers-Danlos Syndrome             | 98249     |
| ERN RITA     | Vasculitis                         | 52759     |
| ERN RITA     | Juvenile Idiopathic Arthritis      | 92        |
| ERN-RND      | Hereditary Spastic Paraplegia      | 685       |
| ERN-RND      | Early-onset generalized limb-onset dystonia | 256 |
| ERN Skin     | Inherited Epidermolysis Bullosa    | 79361     |
| MetabERN     | Phenylketonuria                    | 716       |
| MetabERN     | Fabry Disease                      | 324       |
| VASCERN      | Hereditary Haemorrhagic Telangiectasia | 774    |
| VASCERN      | Marfan syndrome                    | 558       |
| VASCERN      | Vascular Ehlers-Danlos Syndrome    | 286       |

Clinical Lead Identification

For most childhood-onset conditions requiring lifelong care, both paediatric and adult clinical leads were identified. Our findings identified a significant gap in adult service provision for neurodevelopmental conditions such as Neurofibromatosis Type 1. For certain conditions (e.g., Amyotrophic Lateral Sclerosis), an adult-only care pathway was relevant.

Clinical Practice Guidelines

CPGs were identified for 26 of the 29 conditions. However, many were based on lower levels of evidence, focused on a single body system, represented the position of a specific professional group, were over 10 years old or were not written in English.
Core Components of a Care Pathway

Whilst the output from Clinical Leads was heterogenous, core components necessary across all care pathways emerged (Figure 4).

- **Diagnosis’ section features included:** clinical presenting features; diagnostic criteria; tests and investigations required for diagnosis detailed under the medical disciplines responsible to carry these out; red flags for GPs were included where possible.
- **Care’ section features included:** medical disciplines and interventions necessary for patient management; symptomatic and asymptomatic screening; triggers for onward referrals; essential HSCP interventions; delineation of the GP role; links to relevant patient organisation(s).
- **Information’ section features included:** CPGs and references used to inform the care pathway, the Orphanet definition and link for each condition along with Orphacode(s), relevant ERN links and clinical leads information.
- **Resources’ sections were developed containing staff resources and linked services needed to deliver the expected level of care outlined in each pathway, to support their use as a service funding planning tool.**

*Core’ vs ‘as required’ Disciplines*

Clinical leads indicated the need to distinguish between core HSCP disciplines and interventions necessary for routine patient management and ‘as required’ HSCP disciplines and interventions for patients with more complex clinical needs. For example, core HSCP disciplines initially identified for NF1 were Paediatrics, Ophthalmology, Dermatology, Clinical Genetics, Nurse Specialist, Medical Social Work, Occupational Therapy, Speech and Language Therapy, Psychology and Registry management. However, 11 additional ‘as required’ disciplines including Radiology, Surgery and Oncology were also identified and detailed within the care pathway.

**Key Roles**

Clinical leads and patient/service user representatives identified a Nurse Specialist, Medical Social Worker, Psychologist and Registry Manager roles as being essential in all 29 pathways (Table 2). Genetic counselling was considered a core discipline for 27 pathways as these conditions have a major underlying genetic aetiology. Occupational Therapy, Physiotherapy, and/or Speech and Language Therapy were defined as core disciplines in 76% of the care pathways. 45% of pathways included dietetics as a key discipline.
| Disease name                          | Nurse | Specialist | Physio. | Occup. Therapy | Speech and Language Therapy | Psychol. | Medical Social Worker | Gen. Counselling | Database Manager | Dietetics |
|--------------------------------------|-------|------------|---------|----------------|-----------------------------|----------|-----------------------|----------------|-----------------|----------|
| Turner syndrome                      | ✓     | ✓          | ✓       | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Primary Adrenal Insufficiency        | ✓     | ✓          |         | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Glomerular disease                   | ✓     | ✓          | ✓       | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Osteogenesis Imperfecta              | ✓     | ✓          | ✓       | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Hypophosphataemic Rickets            | ✓     | ✓          | ✓       | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Tuberous Sclerosis                   | ✓     | ✓          | ✓       | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Sickle Cell Anaemia                  | ✓     | ✓          |         | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Von Willebrand disease               | ✓     | ✓          |         | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Duchenne Muscular Dystrophy          | ✓     | ✓          | ✓       | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Amyotrophic Lateral Sclerosis        | ✓     | ✓          | ✓       | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Retinitis Pigmentosa                 | ✓     | ✓          |         | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Usher Syndrome                       | ✓     | ✓          | ✓       | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Neurofibromatosis 1                  | ✓     | ✓          | ✓       | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Long QT syndrome                     | ✓     | ✓          |         | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| 22q11.2 deletion syndrome            | ✓     | ✓          | ✓       | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Angelman syndrome                    | ✓     | ✓          | ✓       | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Sarcoidosis                          | ✓     | ✓          |         | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Wilson Disease                       | ✓     | ✓          | ✓       | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Ehlers Danlos - Vascular type        | ✓     | ✓          | ✓       | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Ehlers-Danlos Syndrome               | ✓     | ✓          | ✓       | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Vasculitis                           | ✓     | ✓          |         | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Juvenile Idiopathic Arthritis        | ✓     | ✓          |         | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Hereditary Spastic Paraplegia        | ✓     | ✓          | ✓       | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Early-onset generalized limb-onset dystonia | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Epidermolysis Bullosa                 | ✓     | ✓          | ✓       | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Phenylketonuria                       | ✓     | ✓          |         | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Fabry Disease                         | ✓     | ✓          |         | ✓              | ✓                           | ✓        | ✓                     | ✓              | ✓               | ✓        |
| Disease name                                      | Nurse Specialist | Physio. | Occup. Therapy. | Speech and Language Therapy | Psychol. | Medical Social Worker | Gen. Counselling | Database Manager | Dietetics |
|-------------------------------------------------|------------------|---------|-----------------|-----------------------------|---------|-----------------------|-----------------|-----------------|----------|
| Hereditary Haemorrhagic Telangiectasia           | ✓                |         |                 |                             | ✓       | ✓                     | ✓               | ✓               | ✓        |
| Marfan syndrome                                 | ✓                | ✓       |                 | ✓                           | ✓       | ✓                     | ✓               | ✓               | ✓        |

**Care Coordination**

Patient representatives indicated the importance of identifying an HCP for each care pathway to take on a care co-ordinator role. For example, in the case of sarcoidosis 90% of patients present to a respiratory specialist who manages onward referrals to other specialists, as required. In other pathways, the nurse specialist has a central role as the co-ordinator of MDT care, for example in Epidermolysis Bullosa. In the paediatric 22q11 deletion syndrome, a care coordinator is established as a distinct role that can be occupied by a nurse specialist or other relevant HSCP.

**Patient / Service Users Representatives**

Five online workshops involving patient representatives for 14 care pathways were held, co-hosted by Rare Diseases Ireland and the National Rare Diseases Office. Several major themes emerged, including recognition of the challenges and needs common to all rare disease patients: access to co-ordinated care; the priority for holistic care that recognises patients’ and carers’ psychosocial needs; the value of more timely and local community access to HSCPs with a focus on optimising child development and function; the benefit of support for education, employment and social integration, and the need for support to navigate the welfare system. Common themes also emerged from patient representative feedback on individual care pathways: the central role of Nurse Specialists as a primary point of contact providing education and support for patients and carers and critical liaison with other HCPs; the need for access to psychology support around diagnosis, transition and other major milestones in the patient journey; the key role of HSCPs in fostering wellbeing and quality of life; the value of play therapy to support coping, adaption and compliance; the central role of patient organisations in providing support, information and advice was emphasised across multiple pathways.

**Discussion**

A primary objective of this project was to develop an optimal process for the introduction of national RD care pathways into the Irish healthcare system in the absence of a commonly recognised best practice methodology. Developing a national generic RD care pathway model was a fundamental aspect of this study (see Fig. 2). The aim was to create an adaptable, interactive, and updatable model with the capacity to outline the coordinated interventions by multiple healthcare providers from pre-diagnosis across the entire life-long patient journey. The model can be flexible to allow for inclusion of specific delivery models where they exist and ensuring adaptability to evolving service configuration. For example, in Ireland, interdisciplinary Children’s Disability Network Teams have recently been established, comprising over 20 HSCPs, to provide services and supports for children with complex disabilities. Care pathways can be mapped to their respective patient journeys to evaluate if holistic needs of the affected patient population are adequately addressed (33). Active engagement with health service managers involved in service design, at all stages of care pathway development, facilitates accurate alignment with national service delivery models.

Patient representatives emphasised the importance of a holistic approach to highly specialised care, with a key focus on access to psychosocial care. RD pathways can signpost patients to therapeutic interventions, psychological care and social services, thereby supporting patients and families to navigate education, employment and welfare supports. This is consistent with findings from published surveys across the wider RD patient community which prioritise improved social inclusion, mental health and quality of life as a means to redress the detrimental impact on personal, professional and socioeconomic status experienced by so many people living with a RD (3, 7, 33). Patient representatives attributed high value to HSCP and psychosocial roles. As many rare diseases start in childhood and do not yet have effective treatments the need to optimise child development and function through therapeutic support was considered critical to optimising quality of life. Timely access to local community psychology services was prioritised by patients/service users at key points in the patient journey. Within the Irish healthcare landscape, provision of psychological interventions has tended to be limited to restricted scenarios and often hospital-based; however, psychology services are now provided in each of the 91 Children’s Disability Network Teams that provide community-based services throughout Ireland.

**Gaps in Adult Services**
Challenges in mapping adult Irish clinical experts for lifelong, childhood-onset neurodevelopmental conditions, such as NF1, 22q11 deletion syndrome and Angelman syndrome, revealed significant gaps in adult service provision due to a lack of clear transition pathways. Consequently, GPs are often left to coordinate ongoing management in an ad hoc manner (10). The lack of adult multidisciplinary care to address the complex medical and psychosocial needs of these patients is a primary concern for patients and carers, who often take on the role of care coordinator themselves (6). A focus on delivering adequate co-ordinated adult care for life-long neurodevelopmental conditions is required (34).

**Primary Care**

The role of general practice in the diagnosis, treatment and ongoing care of people with RDs and the need for better communication, more consistent coding nomenclature, shared electronic health records and enhanced education in primary care has been highlighted (10). In Ireland, the establishment of multidisciplinary primary care teams has been core to health policy since 2001 and their role in the care of patients with rare diseases is central (12, 17, 35). Furthermore, the value of enhanced and seamless communication between specialist centres and primary care HCPs in managing patients with rare diseases is consistent with the integrated approach to healthcare delivery that is a core part of the Irish ‘Slaintecare’ reform programme (18).

National RD care pathways can address the self-reported gaps in primary care RD education by facilitating access to reliable RD resources; delineating the role of GPs in RD diagnosis and management; mapping local healthcare system organization for RDs including national CoEs; integrating ERNs for expert opinion and network care (11, 35). They enable local care to be informed by the latest evidence base leading to improved patient outcomes and healthcare service efficiency (33, 36).

**Patient Partnership**

Patient involvement in the development of guidelines and pathways has been reported to enhance the relevance, practicality, and impact of care organised under these clinical support tools (25). Despite the highly heterogeneous nature of rare diseases, the project found through the active engagement of patient representatives, that people living with a rare disease face common needs and challenges. Of importance is the awareness of and access to healthcare professionals and services with sufficient knowledge of their rare condition. This confirms similar findings evidenced across the wider RD community (38). Whilst both patients and professionals have a shared goal, they can hold different but equally valuable perspectives. Building mutual respect for both perspectives on care decisions and service design is fundamental to aligning healthcare services on the needs of the patient locally (25). Notable barriers for meaningful patient-professional partnership are two-fold. Firstly, a perceptional barrier by clinicians who question the value of patient collaboration. However, overtime clinicians have been reported to develop a more positive view on patient involvement (39). Secondly, patients can question how they can best contribute to the development of guidelines and care pathways due to the use of complex medical terminology. These barriers can be overcome but time and tools are needed to support patient-professional partnerships. Patients’ insights are invaluable as they are ‘experts living with the condition’ and can provide a different perspective to that of clinicians (40, 41).

Our study found that involving Rare Diseases Ireland (RDI) as key facilitators was effective in encouraging patient contribution. Patient involvement provides the weight of patients’ opinions and preferences of interventions and treatment, informed by the benefits and harms associated with treatments; empowering patients in decision making about their care; ensuring the holistic needs are understood and addressed (40). Recognition of patients as experts-by-experience with the capacity to co-design and lead in the development of patient-centred care is central and has been evidenced by the European Patient Advocacy Groups (ePAGs) in ERNs.

**Provision of Genetic Services**

Over 70% of RDs have a significant genetic basis (32). Also, RDs with a non-genetic basis there can be significant heritability, indicating the likelihood of genetic susceptibility and/or rare genetic sub forms. Genetic counselling was considered a core discipline for most of the pathways. As the clinical genomics landscape evolves due to improving diagnostic methods and treatments, care pathways need to be flexible to adapt (42). The genetic counselling profession is uniquely placed to support these transitions in best practice and to ensure that ethical principles are followed that consider the implications for patients and their extended family members. As genomics promises to deliver powerful diagnostic solutions, national clinical genetic services struggle to absorb increased demand (43). Mainstreaming of genetic testing is the inevitable consequence. However, the inherent risks of misinterpretation of complex genomic data are evident even for HCPs with formal clinical genetics training and extensive genomic experience (44). Clinical Geneticists and Genetic Counsellors have a central role in education of non-Genetics HCPs to promote the safe delivery of genomic medicine (45).

**Registries**
Inclusion of database managers for registry development and curation was deemed a core requirement in line with ERN priorities. Registries are recognised as an invaluable resource for capturing epidemiological disease information and natural history, identifying patient cohorts available for clinical research, assessing therapeutic outcomes, generating evidence and monitoring CoEs for disease-specific key performance indicators that can be used to gauge ERN activity and impact. Centralised registry development to ensure data interoperability and uniform database structure is essential for integration into the ERN IT system (46). The use of Orphacodes within our care pathways promotes aligned codification with ERN RD registries, which are committed to Orphacode designation as a key parameter, and implementation of the EC eHealth Network Guideline on the electronic exchange of health data under the Cross Border Directive 2011/24/EU (47).

**Accessibility and Dissemination**

The ability to recognise RDs at initial points of contact with patients is a significant challenge (33). Support is also required for primary and secondary care HCPs to ensure safe patient management while patients wait to access specialist tertiary services. Ready access to care pathways at key points of contact across frontline clinical services is critical to maximise their utility. To facilitate this, it is envisaged in our programme that the care pathways will be hosted on a dedicated website which will be accessible through the National Rare Disease Office, Irish Health Service Executive, Orphanet, relevant ERN and national professional and patient organisation websites. This aligns with physicians’ preferences for professionally endorsed channels for accurate RD information dissemination via expert centres and professional associations (11). The positive level of patient engagement in this study augurs well for co-promotion and effective dissemination of care pathways within the RD patient community via patient organisation networks.

By providing access to national care pathways via a dedicated website the interactive capacity of the pathways can be fully realized. Future work will focus on the development of patient-friendly versions and tools to enhance patient access by building on these interactive features. The ‘Rare 2030’ recommendations promote enhanced visibility of best practice guidelines and the importance of accessibility for patients by including a patient ‘lay’ summary that should be co-designed and developed with patient and service users (7).

Centralised, updatable versions of each care pathway will facilitate easy access to the latest guidelines by multiple disciplines across different locations which aligns with the ERN eHealth goal of ensuring the availability of up-to-date information (48). It is proposed that regular future audit by Clinical Leads and Patient Representatives will ensure that new evidence emerging around diagnostics, management and treatment will be captured.

**Implementation**

The impact of developing aspirational care pathways, with a significant number that are not implemented to date, was noted by patient representatives and HCPs as a concern. We propose that detailing the resources required to deliver the care outlined in each pathway, will enable advocacy for commissioning. Significant barriers to successful implementation within local and national services exist with pressures on healthcare systems and demands on clinical time. This study also shows that care pathway development is a time intensive activity requiring dedicated funding to ensure sustainability.

To ensure alignment with national healthcare strategies and effective implementation, further engagement with key national health service stakeholders including primary care, integrated care, digital E-health and disability services is ongoing. The next steps include piloting of individual pathways with follow-up evaluation and revisions for further optimisation. The improved efficiencies of these pathways through shortening the diagnostic journey, enhancing access to appropriate management and intervention and improved patient outcomes, will be evaluated.

**Limitations of the study**

Our methodology aligns with that of the RarERN Path as a framework for collaboration with national clinical experts and patient representatives (27). However, cost analysis of current and proposed care pathways was not within the scope of this study. Detailing of each care pathway by each discipline involved in care would be optimum. However, a pragmatic approach was taken in this study by selecting the most relevant professionals in the specific care pathway.

**Rare 2030 Recommendations**

The ‘Rare 2030 Foresight’ study emphasises the full development and implementation of national RD plans as a primary recommendation with the development of care pathways as key component (7). Specifically, digital care pathways can facilitate the collection and evaluation of patient data, by auditing the outcomes and further developing interventions within each pathway based on outcomes. This
equips frontline clinical services to deliver more cost-effective evidence-based medicine and personalised care leading to better patient outcomes. Furthermore, digital care pathways have the potential to accelerate the development and uptake of RD treatment options by facilitating European-wide clinical trials and research. National care pathway development can promote care co-ordination between HCPs, improve access to specialists and enhance treatment opportunities as highlighted as the top three highest unmet needs by the RD community to be addressed by 2030 (7).

**Conclusion**

This pilot study explored the development of an optimal process for national RD care pathway design in the absence of agreed, common, best practice methodology. Partnership with RD patient representatives and service users was central to the delivery of this study. The high level of engagement experienced from clinical leads and patient organisations highlights the strong endorsement of this care pathway initiative by key RD stakeholders. RD patient needs and health care professional interventions common across all pathways were identified, highlighting the core roles of therapeutic HSCPs, Nurse Specialist, Psychology, Medical Social Work, Database Manager and Genetic Counselling for delivering optimum rare disease care. Effective care pathways offer the best opportunity to translate best practice, evidence-based guidelines into local healthcare services leading to service redesign and more targeted resources to optimise patient health outcomes. It is intended that care pathways will prove to be effective educational, clinical and advocacy tools for general practitioners (GPs), hospital specialists, HSCPs, health service managers, patients and carers. Future research examining the implementation of such care pathways is a priority.

**Declarations**

Ethics approval and consent to participate: Not applicable

Consent for publication: Not applicable

Availability of data and materials: Not applicable

Competing interests: The authors declare that they have no competing interests.

Funding: This work was partially supported by the Orphanet Direct Grant (831390 (2018-2020))

**Authors contributions:**

AJW, DM and EPT analysed the data and interpreted the results. All authors contributed to data capture. AJW, EPT, DM and RM conceived the study design. All authors contributed to the writing of the manuscript.

**Acknowledgements:**

We wish to acknowledge the collaboration of the Clinical Leads and Patient Representatives for the care pathway development and invaluable feedback and support. We would also like to thank Deborah Lambert, Geraldine Sweeney and Ines Hernando (Eurordis) for their helpful input and discussion.

**References**

1. European Council Regulation (EC). No 141/2000 on orphan medicinal products. Available at: http://data.europa.eu/eli/reg/2000/141/oj.
2. Irish National Plan for Rare Diseases 2014-2018, https://assets.gov.ie/37342/da70fc6fadd24425b98311e679f4406b.pdf.
3. Castro R, Senecat J, de Chalendar M, Vajda I, Dan D, Boncz B, et al. Bridging the Gap between Health and Social Care for Rare Diseases: Key Issues and Innovative Solutions. Adv Exp Med Biol. 2017;1031:605–27.
4. Survey of the delay in diagnosis for 8 rare diseases in Europe (EurordisCare 2). 2007 https://www.eurordis.org/sites/default/files/publications/Fact_Sheet_Eurordiscare2.pdf.
5. Rare Diseases UK, The Rare Reality, an insight into the patient and family experiences of rare diseases, 2016. https://www.raredisease.org.uk/media/1588/the-rare-reality-an-insight-into-the-patient-and-family-experience-of-rare-disease.pdf.
6. Simpson A, Bloom L, Fulop NJ, Hudson E, Leeson-Beevers K, Morris S, et al. How are patients with rare diseases and their carers in the UK impacted by the way care is coordinated? An exploratory qualitative interview study. Orphanet J Rare Dis. 2021;16(1):76.
7. Eurordis Rare 2030 Foresight Study 2018-2030. http://www.rare2030.eu.
8. Newsletter OECD, January 11, 2017. Tackling wasteful spending on health. https://www.oecd.org/health/tackling-wasteful-spending-on-health-9789264266414-en.htm,
9. Ramalle-Gómez E, Domínguez-Garrido E, Gómez-Eguilaz M, Marzo-Sola M, Ramón-Trapero JL, Gil-de-Gómez J. Education and information needs for physicians about rare diseases in Spain. Orphanet J Rare Dis. 2020 Jan 17;15(1):18. doi: 10.1186/s13023-019-1285-0.
10. Byrne N, Turner J, Marron R, Lambert DM, Murphy DN, O’Sullivan G, et al. The role of primary care in management of rare diseases in Ireland. Ir J Med Sci. 2020;189(3):771–6.
11. Vandeborne L, van Overbeeke E, Dooms M, De Beleyr B, Huys I. Information needs of physicians regarding the diagnosis of rare diseases: a questionnaire-based study in Belgium. Orphanet J Rare Dis. 2019;14(1):99.
12. Walton H, Hudson E, Simpson A, Ramsay AIG, Kai J, Morris S, et al. Defining Coordinated Care for People with Rare Conditions: A Scoping Review. Int J Integr Care. 2020;20(2):14.
13. Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: A systematic review of cost of illness evidence. Health Policy. 2015;119(7):964–79.
14. Gunne E, McGarvey C, Hamilton K, Treacy E, Lambert DM, Lynch SA. A retrospective review of the contribution of rare diseases to paediatric mortality in Ireland. Orphanet J Rare Dis. 2020;15(1):311.
15. Lampe C, Dionisi-Vici C, Bellettato CM, Paneghetti L, van Lingen C, Bond S, et al. The impact of COVID-19 on rare metabolic patients and healthcare providers: results from two MetabERN surveys. Orphanet J Rare Dis. 2020;15(1):341.
16. Talarico R, Aguilera S, Alexander T, Amoura Z, Antunes AM, Amaud L, et al. The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. Nat Rev Rheumatol. 2021;17(3):177–84.
17. Health Service Executive, Model of Care for Rare Diseases. 2019. https://www.lenus.ie/handle/10147/626904.
18. Department of Health Sláintecare Implementation Strategy and Action. Plan 2021-2023. Dublin. Ireland: Government Publications; 2021. https://www.gov.ie/en/campaigns/slaintecare-implementation-strategy/.
19. EU Council 2009. Council Recommendation of 8 June 2009 (2009/C 151/02) on an action in the field of rare diseases. European Commission 3rd July 2009. Report No.: ISSN 1725-2423. European Council 2009 Recommendation on Action in the field of Rare Diseases.
20. European Commission Expert Group on Rare Diseases. Recommendations to support the integration of Rare Diseases into social services. https://ec.europa.eu/health/sites/default/files/rare_diseases/docs/recommendations_socialservices_policies_en.pdf.
21. European Reference Networks. https://ec.europa.eu/health/ern_en.
22. Statement of the EC ERN Board of Member States on Integration of the European Reference Networks to the healthcare systems of Member States. (2019). https://ec.europa.eu/health/sites/default/files/ern/docs/integration_healthcaresystems_annex_en.pdf.
23. Vanhaeckt K, Bollmann M, Bower K, Gallagher C, Gardini A, Guezo J. Prevalence and use of clinical pathways in 23 countries – an international survey by the European pathway association. Journal of integrated Care Pathways. 2006;10:28–34.
24. Lawal AK, Rotter T, Kinsman L, Machotta A, Ronellenfitsch U, Scott SD, et al. What is a clinical pathway? Refinement of an operational definition to identify clinical pathway studies for a Cochrane systematic review. BMC Med. 2016 Feb;23:14:35.
25. Bolz-Johnson M, Kenny T, Le Cam Y, Hernando I. Our greatest untapped resource: our patients. J Community Genet. 2021 Apr;12(2):241–6. doi:10.1007/s12687-021-00524-5.
26. Somanadhan S, Nicholson E, Dorris E, Brinkley A, Kennan A, Treacy E, et al. Rare Disease Research Partnership (RAinDRoP): a collaborative approach to identify research priorities for rare diseases in Ireland. HRB Open Res. 2020 Nov 11;3:13. doi: 10.12688/hrbpopenres.13017.2.
27. Talarico R, Cannizzo S, Lorenzoni V, Marinello D, Palla I, Pirri S, et al. RarERN Path: a methodology towards the optimisation of patients' care pathways in rare and complex diseases developed within the European Reference Networks. Orphanet J Rare Dis. 2020;15(1):347.
28. Perrier L, Buja A, Mastrangelo G, Vecchiato A, Sandonà P, Ducimetière F, et al. Clinicians’ adherence versus non-adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions. BMC Health Serv Res. 2012;12:82.
29. Bristow R, Chang J, Argyrios Z, Anthon-Culver H. NCCN treatment guidelines for ovarian cancer: A population-based validation study of structural and process quality measures. Gynecol Oncol 2013;130.
30. Lancaster E, Wick E. Standardized Care Pathways as a means to Improve Patient Safety. Surg Clin North Am. 2021;101(1):49–56.
31. Pavan S, Rommel K, Mateo Marquina ME, Höhn S, Lanneau V, Rath A. Clinical Practice Guidelines for Rare Diseases: The Orphanet Database. PLoS One. 2017 Jan 18;12(1):e0170365. doi: 10.1371/journal.pone.0170365.
32. Nguengang Wakap S, Lambert DM, Olyr A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165–73.
33. Tumiene B, Graessner H. Rare disease care pathways in the EU: from odysseys and labyrinths towards highways. J Community Genet. 2021;12(2):231–9.
34. Fung WL, Butcher NJ, Costain G, Andrade DM, Boot E, Chow EW, et al. Practical guidelines for managing adults with 22q11.2 deletion syndrome. Genet Med. 2015;17(8):599–609.
35. Engel PABS, Broback M, Boine N. Physician and patient perceptions regarding physician training in rare diseases: The need for stronger educational initiatives for physicians. J Rare Disorders. 2013;1:1–15.
36. Héon-Klin V. European Reference networks for rare diseases: what is the conceptual framework? Orphanet J Rare Dis. 2017;12(1):137.
37. Bolz-Johnson M, Meek J, Hoogerbrugge N. "Patient Journeys": improving care by patient involvement. Eur J Hum Genet. 2020;28(2):141–3.
38. Stesini S, Paneghetti L, Lampe C, Betti G, Bond S, Bellettato CM, et al. Social and medical needs of rare metabolic patients: results from a MetabERN survey. Orphanet J Rare Dis. 2021;16(1):336.
39. Chalmers JD, Timothy A, Polverino E, Almagro M, Ruddy T, Powell P, et al. Patient participation in ERS guidelines and research projects: the EMBARC experience. Breathe (Sheff). 2017;13(3):194–207.
40. Menon D, Stafinski T, Dunn A, Wong-Rieger D. Developing a patient-directed policy framework for managing orphan and ultra-orphan drugs throughout their lifecycle. Patient. 2015;8(1):103–17.
41. Armstrong MJ, Mullins CD, Gronseth GS, Gagliardi AR. Recommendations for patient engagement in guideline development panels: A qualitative focus group study of guideline-naive patients. PLoS One. 2017;12(3):e0174329.
42. de Wert G, Dondorp W, Clarke A, Dequeker EMC, Cordier C, Deans Z, van El CG, et al. Opportunistic genomic screening. Recommendations of the European Society of Human Genetics. Eur J Hum Genet. 2021 Mar;29(3):365–77.
43. Bruel AL, Nambot S, Quéré V, Vitobello A, Thevenon J, Assoum M, et al. Increased diagnostic and new genes identification outcome using research reanalysis of singleton exome sequencing. Eur J Hum Genet. 2019;27(10):1519–31.
44. Vrijenhoek T, Tonisson N, Kääriäinen H, Leitsalu L, Rigter T. Clinical genetics in transition—a comparison of genetic services in Estonia, Finland, and the Netherlands. J Community Genet. 2021;12(2):277–90.
45. Middleton A, Taverner N, Moreton N, Rizzo R, Houghton C, Watt C, Horton E, Levene S, Leonard P, Melville A, Ellis S, Tripathi T, Patch C, Jenkins E, Lawton P, Monkan J. The Genetic Counsellor Role in the United Kingdom. A statement from the Association of Genetic Nurses and Counsellors (AGNC), August 2020 Endorsed by the Genetic Counsellor Registration Board (GCRB) and Academy for Healthcare Science (AHCS).
46. Bassanese G, Wlodkowski T, Servais A, Heidet L, Roccatallo D, Emma F, et al. The European Rare Kidney Disease Registry (ERKReg): objectives, design and initial results. Orphanet J Rare Dis. 2021;16(1):251.
47. Network Guideline on the electronic exchange of health data under the Cross Border. Directive 2011/24/EU (Release 3, June 2021) https://ec.europa.eu/health/sites/default/files/ehealth/docs/ehn_guidelines_patientsummary_en.pdf.
48. Gulhan I. A unique e-health and telemedicine implementation: European Reference Networks for rare diseases. J Public Health, 2019. p. 223–5.
49. Hardiman O. Major advances in amyotrophic lateral sclerosis in 2020. Lancet Neurol. 2021 Jan;20(1):14–5.

Figures
Figure 1

National Rare Disease Care Pathway Infographic
Figure 2

Rare Disease Care Pathway Patient Journey infographic
Figure 3

Lucid Chart care pathway model of the Amyotrophic Lateral Sclerosis Care Pathway (ref 49).
Figure 4

Core Components of a care pathway

- Diagnostic criteria
- Clinical presentation (including common signs & symptoms)
- Red flags for GPs
- Laboratory tests
- Genetic tests
- Investigations eg. ECG
- Scans eg. CT
- Disciplines involved in diagnosis

- Core medical disciplines required for routine management
- ‘As required’ medical disciplines for complex clinical needs
- Co-ordinating clinical specialty eg. Developmental Paediatrician for NF1
- Surveillance i.e. asymptomatic screening including at what stage, how often
- Symptomatic screening – triggered by what, who to screen & refer on?
- Treatment for symptoms
- Prophylactic treatment
- Follow-up for at-risk family members
- Specific advice / management for pregnancy, anaesthetic, sick days
- GP role
- Database manager
- Health and social care professionals role
- Psychosocial support eg. medical social work, psychology and social care information links
- Validated national and international patient organisation links
- Care delivery location

- Orphanet(s)
- Orphanet definition of the condition
- Orphanet link for each condition
- Clinical Practice Guidelines and medical references used to inform the care pathway
- Links to relevant European Reference Networks websites
- Links to ERN endorsed disease-specific resources
- Staff resources (including linked services) required to deliver the care outlined in the care pathway eg. for 50 patients
- Clinical Lead names and institution